title: Effect of methotrexate on Th1 and Th2 immune responses in mice.
abstract: We investigated the effect of the anti-rheumatic drug methotrexate (MTX) on Th1 and Th2 immune responses in mice. For this investigation, mice were immunized subcutaneously at the base of the tail with ovalbumin (OVA) emulsified with complete Freund's adjuvant (day 0). Varying doses of MTX were orally administered daily from days 0 to 20. On day 21, anti-OVA IgG2a and interferon-gamma (IFN-gamma) as indicators of Th1 responses and anti-OVA IgG1 and interleukin-10 (IL-10) as those of Th2 responses were measured. The results showed that treatment with MTX was followed by decreases in OVA-specific IgG and proliferation of spleen cells to the antigen. The anti-rheumatic drug inhibited both anti-OVA IgG2a and IgG1 production, although the inhibitory effect of MTX on the antigen-specific IgG2a production appeared to be greater than that on IgG1 production. IFN-gamma, but not IL-10, secretion was markedly downregulated by MTX. Administration of MTX resulted in suppression of antigen (OVA)-induced arthritis in mice. The suppression of the joint inflammation by MTX was associated with inhibition of OVA-specific proliferative responses of spleen cells, anti-OVA IgG, IgG2a and IgG1 production, and IFN-gamma and IL-10 secretion, although more pronounced decreases in IgG2a and IFN-gamma were observed compared with those in IgG1 and IL-10 in MTX-treated mice. These results indicate that MTX appears to suppress Th1 and, to a lesser extent, Th2 immune responses and its anti-arthritic effect on human rheumatoid arthritis might be at least in part explained by down-regulation of Th1 responses involved in the disease.
authors.affiliation: Department of Pharmacology, Kobe Pharmaceutical University, Kobe, Hyogo 658-8558, Japan.
authors.forename: Kouya
authors.initials: K
authors.lastname: Yamaki
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Uchida
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Harada
authors.forename: Xiaojuan
authors.initials: X
authors.lastname: Li
authors.forename: Rie
authors.initials: R
authors.lastname: Yanagisawa
authors.forename: Hirohisa
authors.initials: H
authors.lastname: Takano
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Hayashi
authors.forename: Shinji
authors.initials: S
authors.lastname: Taneda
authors.forename: Yoki
authors.initials: Y
authors.lastname: Mori
authors.forename: Shin
authors.initials: S
authors.lastname: Yoshino
mesh_terms: D000284:Administration, Oral; D000818:Animals; D018501:Antirheumatic Agents / Q000494:pharmacology*; D005260:Female; D007107:Immune System / Q000187:drug effects*; D007371:Interferon-gamma / Q000378:metabolism; D008727:Methotrexate / Q000494:pharmacology*; D051379:Mice; D008811:Mice, Inbred DBA; D010047:Ovalbumin / Q000276:immunology; D013154:Spleen / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D018417:Th1 Cells / Q000187:drug effects* / Q000276:immunology; D018418:Th2 Cells / Q000187:drug effects* / Q000276:immunology
chemical_list: D018501:Antirheumatic Agents; D007371:Interferon-gamma; D010047:Ovalbumin; D008727:Methotrexate